Ofer Gonen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Burn treatment company MediWound s stock soars amid Israel s war in Gaza

The company expects to generate $24 million in sales this year, up from $19 million in 2023

Israel generalOfer gonenUs department of defenseDepartment of defenseIsrael based mediwound

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Kellie hansonHani luxenburgOfer gonenCompany on linkedinUs armyExchange commissionDevelopment of the nexobridHealing societyMediwound ltdUs department of defense doDrug administrationEuropean wound management associationEuropean medicines agencyChief executive officerRecent developmentsUpcoming milestones

Ofer Gonen, Author at MedCity News

Ofer Gonen, Author at MedCity News
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

Israel generalOfer gonenHebrew university of jerusalemArte venture groupIsraeli defenseAnatomy medical technologies fundTel aviv universityBiomedical investments ltdClal biotechnology industries ltdMediwound ltdClal biotechnology industriesAnatomy medical technologiesGeneral managerHebrew universityWeight lossMedical devices

MediWound (MDWD) Announces FDA Acceptance of the Supplement to the NexoBrid BLA

MediWound (MDWD) Announces FDA Acceptance of the Supplement to the NexoBrid BLA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ofer gonenMediwound ltdHuman servicesDrug administrationDevelopment authorityBiomedical advanced researchUs department of healthAdministration for strategic preparednessChildren innovation debridement studyStrategic preparedness

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S. NexoBrid is already approved for use for burn patients across all age groups in Europe and Japan YAVNE, Israel, Jan. 09, 2024 (GLOBE NEWSWIRE) MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Food and Drug Administration (FDA) has completed the

United statesHani luxenburgOfer gonenMediwound ltdEuropean unionBiomedical advanced researchLifesci advisorsAdministration for strategic preparednessHuman servicesDevelopment authorityDrug administrationUs department of healthExchange commissionChildren innovation debridement studyStrategic preparednessQuarterly reports